阿斯利康(AZN.US)双抗1类新药在中国获批临床

智通财经网02-06

智通财经APP获悉，近日，中国国家药监局药品审评中心（CDE）官网公示显示，阿斯利康(AZN.US)申报的1类新药注射用AZD1163获批临床，拟开发治疗类风湿关节炎。据悉，AZD1163是一种新型双特异性抗体，可抑制细胞外肽基精氨酸脱亚胺酶（PAD）2和4的活性，这两种酶在类风湿关节炎（RA）患者中负责蛋白质瓜氨酸化。在易感个体中，瓜氨酸化蛋白会激活T细胞驱动的一系列事件，促进B细胞成熟与活化，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2609552481?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-06 14:51","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2609552481","market":"hk","top_or_hot":-1,"title":"阿斯利康(AZN.US)双抗1类新药在中国获批临床","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，近日，中国国家药监局药品审评中心（CDE）官网公示显示，阿斯利康(AZN.US)申报的1类新药注射用AZD1163获批临床，拟开发治疗类风湿关节炎。据悉，AZD1163是一种新型双特异性抗体，可抑制细胞外肽基精氨酸脱亚胺酶（PAD）2和4的活性，这两种酶在类风湿关节炎（RA）患者中负责蛋白质瓜氨酸化。在易感个体中，瓜氨酸化蛋白会激活T细胞驱动的一系列事件，促进B细胞成熟与活化，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1402474.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阿斯利康(AZN.US)双抗1类新药在中国获批临床</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阿斯利康(AZN.US)双抗1类新药在中国获批临床\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-06 14:51 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1402474.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，近日，中国国家药监局药品审评中心（CDE）官网公示显示，阿斯利康(AZN.US)申报的1类新药注射用AZD1163获批临床，拟开发治疗类风湿关节炎。据悉，AZD1163是一种新型双特异性抗体，可抑制细胞外肽基精氨酸脱亚胺酶（PAD）2和4的活性，这两种酶在类风湿关节炎（RA）患者中负责蛋白质瓜氨酸化。在易感个体中，瓜氨酸化蛋白会激活T细胞驱动的一系列事件，促进B细胞成熟与活化，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1402474.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1402474.html","article_id":"2609552481","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609552481","pubTimestamp":1770360715,"columns":[{"name":"产品发布","id":31,"label_key":"productRelease"}],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，近日，中国国家药监局药品审评中心官网公示显示，阿斯利康申报的1类新药注射用AZD1163获批临床，拟开发治疗类风湿关节炎。2025 ACR年会首次公布了AZD1163在健康志愿者中的安全性、耐受性、药代动力学特性及其对系统性PAD酶活性影响的药效学数据研究。研究表明，AZD1163的暴露量呈剂量比例性增加，皮下给药后最大浓度出现在第10天。本次该产品在中国获批临床，意味着其在中国的临床研究即将开展。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4007":"制药","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4568":"美国抗疫概念","BK4588":"碎股","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","AZN":"阿斯利康","BK4585":"ETF&股票定投概念","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC"},"translate_title":"AstraZeneca (AZN.US) double antibody class 1 new drug approved for clinical use in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1.5},"content_text":"智通财经APP获悉，近日，中国国家药监局药品审评中心（CDE）官网公示显示，阿斯利康(AZN.US)申报的1类新药注射用AZD1163获批临床，拟开发治疗类风湿关节炎。据悉，AZD1163是一种新型双特异性抗体，可抑制细胞外肽基精氨酸脱亚胺酶（PAD）2和4的活性，这两种酶在类风湿关节炎（RA）患者中负责蛋白质瓜氨酸化。在易感个体中，瓜氨酸化蛋白会激活T细胞驱动的一系列事件，促进B细胞成熟与活化，进而产生致病性抗瓜氨酸化蛋白抗体（ACPA）。ACPA与更差的预后相关，常表现为更严重的关节损伤和快速进展的病程。在体外实验中，AZD1163能抑制RA患者血清和滑液中存在的蛋白质瓜氨酸化及升高的PAD活性。2025 ACR年会首次公布了AZD1163在健康志愿者中的安全性、耐受性、药代动力学特性及其对系统性PAD酶活性影响的药效学数据研究。研究表明，AZD1163的暴露量呈剂量比例性增加，皮下给药后最大浓度出现在第10天。皮下给药的生物利用度估计为65%。平均系统清除率为0.15升/天，平均消除半衰期为38天。观察到对PAD2/4活性显著且剂量依赖性的抑制，最大抑制率超过95%，证实了靶标结合。在AZD1163接受者中，抗药物抗体（ADA）发生率较低，为6.7%。不良事件较少，剂量递增耐受性良好。这项针对抑制PAD2/4酶的新型双特异性抗体的首次人体研究表明，在健康志愿者中每两周给药一次的AZD1163耐受性良好，在所研究的剂量范围内显示出良好的药代动力学特征。通过离体血浆中PAD2/4活性的抑制证明了靶标结合。此项1期研究获得的结果支持在RA患者中进一步评估AZD1163。根据ClinicalTrials官网，阿斯利康正在开展AZD1163治疗类风湿关节炎患者的一项2期临床研究。本次该产品在中国获批临床，意味着其在中国的临床研究即将开展。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609552481","isCrawlerRequest":true}